Will They or Won’t They? What to Know Ahead of the Fed’s Big Decision TodayMar 22, 2023 | Educational
Read this before the Fed announces its next move...
Read this before the Fed announces its next move…
The ‘Shiny Ball Syndrome’ Trap in AI Investing Is Real. Here’s How to Avoid It.
Mar 21, 2023 | Educational
Plus an AI makeover for a 38-year-old product…
3 Profit Opportunities After the Regional Bank Beatdown
Mar 20, 2023 | Educational
To make things simple, we can look within the iShares U.S. Regional Banks ETF (IAT), which will give us a list of 37 regional bank stocks to analyze with our proprietary investing tools to see what potential winners are hiding within its holdings.
Bank Watch: Stock Chatter Hinted SIVB and SBNY Would Fail. These Two Could Be Next.
Mar 17, 2023 | Educational
So far, stock chatter hinted which banks would fail. These two could be next…
The Bottom Line for Investors on the Bank Failures
Mar 16, 2023 | Educational
: Is this a crisis – or an opportunity? Hear from three experts in today’s TradeSmith Daily…
The Three Most Important Words of the Week: Consumer Price Index
Mar 15, 2023 | Educational
Here’s where to invest now…
The Data Point That Matters the Most for the Direction of the Stock Market
Mar 14, 2023 | Educational
As I was talking with Quantum Edge Pro Editor Jason Bodner about all this, he assured me that there was no need to suffer from information overload, as he believes just one data point should be focused on the most.
LikeFolio Begins Coverage on DIN and LZB – What You Need to Know About Both Stocks
Mar 10, 2023 | Educational
In February, LikeFolio began covering 13 new companies, and while we can’t go over each and every one, there are two in particular that we want to share: Dine Brands Global (INC) and La-Z-Boy Inc. (LZB).
One Company at the Frontier of Gene-Editing Technology (Ticker Revealed Inside)
Mar 09, 2023 | Educational
Imagine how much money could be made by investing in companies that could provide lifelong cures to genetic conditions. With this company, you may not have to imagine.
Gene-Editing Collaboration Is What’s Next for Moderna – Here’s What TradeSmith’s Tools Say about the Stock
Mar 08, 2023 | Educational
Now, to be clear, biotech investing is notoriously risky, as it can cost hundreds of millions of dollars and years to develop a product that ultimately may not pass FDA approval. But with TradeSmith’s tools and proprietary algorithms, we’re able to help our readers go past the news and measure what ultimately matters.